CA 19-9 in the therapy monitoring and follow-up of locally advanced cancer of the exocrine pancreas treated with radiochemotherapy

Anticancer Research

Volumn 23, Issue 2 A, 2003, Pages 835-840

  Micke, Oliver ^a,b   Bruns, Frank ^a   Schäfer, Ulrich ^a   Kurowski, Rene ^a   Horst, Eckehard ^a   Willich, Norman ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b Klinik und Poliklinik   (Germany)

Author keywords

CA 19 9; Pancreatic carcinoma; Radiochemotherapy

Indexed keywords

CA 19-9 ANTIGEN; FLUOROURACIL; FOLINIC ACID;

ADULT; ADVANCED CANCER; AGED; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CONFERENCE PAPER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PANCREAS CANCER; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; STATISTICAL SIGNIFICANCE;

ADENOCARCINOMA; ADULT; AGED; CA-19-9 ANTIGEN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 0038199686     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (74)

1. Mokovitzky J: The occurrence of the carbohydrate antigen 19-9 in the organism of man. In: A. Current Tumor Diagnosis: Applications, Clinical Relevance, Research, Trends (Klapdor R, ed. München Bern Wien New York, W. Zuckschwerdt Verlag, 1994; pp 808-810.
2. Gattani AM, Mandeli J and Bruckner HW: Tumor markers in patients with pancreatic carcinoma. Cancer 78: 57-62, 1996.
3. Haglund C, Roberts PJ, Jalanko H and Kuusela P: Tumour markers CA 19-9 and CA 50 in digestive tract malignancies. Scand J Gastroenterol 27: 169-174, 1992.
4. Koprowski H, Herlyn M, Steplewski Z and Sears HF: Specific antigen in serum of patients with colon carcinoma. Science 212: 53-55, 1981.
5. Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D and Fuhrer P: Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet 5: 957-971, 1979.
6. Del Villano BC, Brennan S, Brock P, Bucher C, Liu V, McClure M, Rake B, Space S, Westrick B, Schoemaker H and Zurawski VR Jr.: Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9. Clin Chem 29: 549-552, 1983.
7. Steinberg W: The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol 85: 350-355, 1990.
8. Spila A, Ferroni P, Cosimelli M et al.: Comparative analysis of CA 242 and CA 19-9 serum tumor markers in colorectal cancer patients. A longitudinal evaluation. Anticancer Res 21:1263-1270, 2001.
9. Lopez JB, Royan GP, Lakhwani MN, Mahadaven M and Timor J: CA 72-4 compared with CEA and CA 19-9 as a marker of some gastrointestinal malignancies. Int J Biol Markers 14: 172-177, 1999.
10. Wilson AP, Van Dalen A, Sibley PE, Kasper LA, Durham AP and el Shami AS: Multicentre tumour marker reference range study. Anticancer Res 19: 2749-2752, 1999.
11. Griesenberg D, Nurnberg R, Bahlo M and Klapdor R: CEA, TPS, CA 19-9 and CA 72-4 and the fecal occult blood test in the preoperative diagnosis and follow-up after resective surgery of colorectal cancer. Anticancer Res 19: 2443-2450, 1999.
12. Reiter W, Stieber P, Reuter C, Nagel D, Lau-Wemer U and Lamerz R: Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer. Anticancer Res 20: 5195-5198, 2000.
13. Brockmann J, Emparan C, Hernandez CA, Sulkowski U, Dietl KH, Menzel J, Wolters H, Glodny B and Senninger N: Gall bladder bile tumor marker quantification for detection of pancreato- biliary malignancies. Anticancer Res 20: 4941-4947, 2000.
14. Ohara K, Tatsuzaki H, Molotkova NG et al.: Utility of serum CA 19-9 monitoring in preoperative radiotherapy for pancreatic cancer. Hepatogastroenterology 48: 859-863, 2001.
15. Nazli O, Bozdag AD, Tansug T, Kir R and Kaymak E: The diagnostic importance of CEA and CA 19-9 for the early diagnosis of pancreatic carcinoma. Hepatogastroenterology 47: 1750-1752, 2000.
16. Horst E, Micke O, Schdfer U and Willich N: Serum copper and zinc levels, nutritional status and CA 19-9 levels during and after hyperfractionated radiochemotherapy (HRCT) of patients with locally advanced pancreatic adenocarcinoma. Trace Elem Electrolytes 17: 202-205, 2000.
17. Montgomery RC, Hoffman JP, Riley LB, Rogatko A, Ridge JA and Eisenberg BL: Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas. Ann Surg Oncol 4: 551-556, 1997.
18. Satake K and Takeuchi T: Comparison of CA19-9 with other tumor markers in the diagnosis of cancer of the pancreas. Pancreas 9: 720-724, 1994.
19. Katz A, Hanlon A, Lanciano R, Hoffman J and Coia L: Prognostic value of CA 19-9 levels in patients with carcinoma of the pancreas treated with radiotherapy. Int J Radiat Oncol Biol Phys 41: 393-396, 1998.
20. Heinemann V, Schermuly MM, Stieber P, Schulz L, Jungst D, Wilkowski R and Schalhorn A: CA19-9: a pedictor of response in pancreatic cancer treated with gemcitabine and cisplatin. Anticancer Res 19: 2433-2435, 1999.
21. Hamori J, Arkosy P, Lenkey A and Sapy P: The role of different tumor markers in the early diagnosis and prognosis of pancreatic carcinoma and chronic pancreatitis. Acta Chir Hung 36: 125-127, 1997.
22. Klapdor R, Harms F, Bahlo M, Arps H and Dietel M: Tumor marker secretion (CA 19-9, CEA, CA 125) by xenografts of eight different human pancreatic carcinomas compared to the human tumors. Strahlenther Onkol 165: 496-497, 1989.
23. Von Rosen A, Linder S, Harmenberg U and Wiechel KL: Clinical relevance of tumour markers CA 19-9 and CA-50 in sera from patients with pancreatic duct carcinoma. Surg Oncol 1: 109-113, 1992.
24. Haglund C, Roberts PJ, Kuusela P, Scheinin TM, Makela O and Jalanko H: Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer. Br J Cancer 53: 197-202, 1986.
25. Haglund C, Kuusela P and Roberts PJ: Tumour markers in pancreatic cancer. Ann Chir Gynaecol 78: 41-53, 1989.
26. Moroz GS and Les'kiv IM: The diagnostic value of determining the level of the carbohydrate antigen 19-9 in pancreatic cancer. Klin Khir 2: 34-35, 1993.
27. Kokhanenko N, Ignashov AM, Varga EV, Polkanova MS, Aleshina LA, Kimbarovskaia AA, Osipenko SK and Lebedev EG: Role of the tumor markers CA 19-9 and carcinoembryonic antigen (CEA) in diagnosis, treatment and prognosis of pancreatic cancer. Vopr Onkol 47: 294-297, 2001.
28. Schwenk J and Makovitzky J: Tissue expression of the cancer-associated antigens CA 19-9 and CA-50 in chronic pancreatitis and pancreatic carcinoma. Int J Pancreatol 5: 85-98, 1989.
29. Safi F, Roscher R and Beger HG: The clinical relevance of the tumor marker CA 19-9 in the diagnosing and monitoring of pancreatic carcinoma. Bull Cancer 77: 83-91, 1990.
30. Fritsche HA Jr and Gelder FB: Serum tumor markers for pancreatic carcinoma. Immunol Ser 53: 289-296, 1990.
31. DelMaschio A, Vanzulli A, Sironi S, Castrucci M, Mellone R, Staudacher C, Carlucci M, Zerbi A, Parolini D, Faravelli A et al.: Pancreatic cancer versus chronic pancreatitis: diagnosis with CA 19-9 assessment, US, CT, and CT-guided fine-needle biopsy. Radiology 178: 95-99, 1991.
32. Malesci A, Montorsi M, Mariani A, Santambrogio R, Bonato C, Bissi O, Tacconi M, Wizemann G and Spina G: Clinical utility of the serum CA 19-9 test for diagnosing pancreatic carcinoma in symptomatic patients: a prospective study. Pancreas 7: 497-502, 1992.
33. Schulze G: The tumor marker tumor M2-PK: an application in the diagnosis of gastrointestinal cancer. Anticancer Res 20: 4961-4964, 2000.
34. EGTM: Tumour markers in gastrointestinal cancers - EGTM recommendations. European Group on Tumour Markers. Anticancer Res 19: 2811-2815, 1999.
35. Fateh-Moghadam A, Stieber P: Tumormarker und Ihr Sinnvoller Einsatz, 2nd ed. Marloffstein-Rathsberg, Jürgen Hartmann Verlag, 1993.
36. Safi F, Roscher R and Beger HG: Tumor markers in pancreatic cancer. Sensitivity and specificity of CA 19-9. Hepatogastroenterology 36: 419-423, 1989.
37. Micke O, Schafer U and Willich N: Persistent elevation of CA 19-9 levels in a patient with an extended retroperitoneal dermoid. Anticancer Res 19: 2717-2720, 1999.
38. Halm U, Rohde N, Klapdor R, Reith HB, Thiede A, Etzrodt G, Mossner J and Keller T: Improved sensitivity of fuzzy logic based tumor marker profiles for diagnosis of pancreatic carcinoma versus benign pancreatic disease. Anticancer Res 20: 4957-4960, 2000.
39. Goetz M and Steen PD: False elevation of CA 19-9 levels in a patient with a history of pancreatic cancer. Am J Gastroenterol 92: 1390-1391, 1997.
40. Akdogan M, Sasmaz N, Kayhan B, Biyikoglu I, Disibeyaz S and Sahin B: Extraordinarily elevated CA19-9 in benign conditions: a case report and review of the literature. Tumori 87: 337-339, 2001.
41. Benharnou PY, Vuillez JP, Halimi S, Meffre G and Bachelot I: Influence of metabolic disturbances of diabetes mellitus on serum CA 19-9 tumor marker. Diabete Metab 17: 39-43, 1991.
42. Bottger T, Hassdenteufel A, Boddin J, Kuchle R, Junginger T and Prellwitz W: Value of the CA 19-9 tumor marker in differential diagnosis of space- occupying lesions in the head of the pancreas. Chirurg 67: 1007-1011, 1996.
43. Cerwenka H, Aigner R, Bacher H, Werkgartner G, el-Shabrawi A, Quehenberger F and Mischinger HJ: TUM2-PK (pyruvate kinase type tumor M2), CA19-9 and CEA in patients with benign, malignant and metastasizing pancreatic lesions. Anticancer Res 19: 849-851, 1999.
44. Minghini A, Weireter LJ Jr and Perry RR: Specificity of elevated CA 19-9 levels in chronic pancreatitis. Surgery 124: 103-105, 1998.
45. Tolliver BA and O'Brien BL: Elevated tumor-associated antigen CA 19-9 in a patient with an enlarged pancreas: does it always imply malignancy? South Med J 90: 89-90, 1997.
46. Yoshida EM, Scudamore CH, Erb SR, Owen DA and Silver HK: Markedly elevated serum CA 19-9 levels in a case of chronic pancreatitis. Can J Surg 38: 83-86, 1995.
47. Osswald BR, Klee FE and Wysocki S: The reliability of highly elevated CA 19-9 levels. Dis Markers 11: 275-278, 1993.
48. Cooperman AM: Pancreatic cancer: the bigger picture. Surg Clin North Am 81: 557-574, 2001.
49. Brand R: The diagnosis of pancreatic cancer. Cancer J 7: 287-297, 2001.
50. Sharma BC, Bhasin DK, Sethi A, Vashishta RK, Gupta NM and Singh K: Extended survival of carcinoma head of pancreas following palliative treatment. Trop Gastroenterol 20: 140-141, 1999.
51. Ginsberg GG: New developments in pancreatic cancer. Semin Gastrointest Dis 11: 162-167, 2000.
52. Barkin JS and Goldstein JA: Diagnostic and therapeutic approach to pancreatic cancer. Biomed Pharmacother 54: 400-409, 2000.
53. Beger HG, Gansauge F and Leder G: Pancreatic cancer: Who benefits from curative resection? Can J Gastroenterol 16: 117-120, 2002.
54. Cellini N, Costamagna G, Morganti AG, Valentini V, Macchia G, Mutignani M, Pandolfi M and Trodella L: Concomitant radiochemotherapy in unresectable carcinoma of the exocrine pancreas: cost-effectiveness analysis. Rays 24: 447-452, 1999.
55. Cellini N, Trodella L, Valentini V, Doglietto GB, Morganti AG, Ziccarelli P, Alfieri S, Bossola M, Brizi MG and Crucitti F: Radiotherapy, local control and survival in carcinomas of the exocrine pancreas. Rays 23: 528-534, 1998.
56. Cellini N, Valentini V, Trodella L, Balducci M, Morganti AG and Turriziani A: Carcinoma of the pancreatic head area. Therapy: concomitant radiochemotherapy. Rays 20: 350-359, 1995.
57. McGinn CJ and Zalupski MM: Combined-modality therapy in pancreatic cancer: current status and future directions. Cancer J 7: 338-348, 2001.
58. Wiegel T, Runkel N, Frommhold H, Rube C and Hinkelbein W: Radiotherapeutic strategies in the multimodal therapy of resectable and nonresectable pancreatic carcinoma. Strahlenther Onkol 176: 299-306, 2000.
59. Prott FJ, Schonekaes K, Preusser P, Ostkamp K, Wagner W, Micke O, Potter R, Sulkowski U, Rube C, Berns T and Willich N: Combined modality treatment with accelerated radiotherapy and chemotherapy in patients with locally advanced inoperable carcinoma of the pancreas: results of a feasibility study. Br J Cancer 75: 597-601, 1997.
60. Ikeda M, Okada S, Tokuuye K, Ueno H and Okusaka T: Prognostic factors in patients with locally advanced pancreatic carcinoma receiving chemoradiotherapy. Cancer 91: 490-495, 2001.
61. Malesci A, Tommasini MA, Bonato C, Bocchia P, Bersani M, Zerbi A, Beretta E and Di Carlo V: Determination of CA 19-9 antigen in serum and pancreatic juice for differential diagnosis of pancreatic adenocarcinoma from chronic pancreatitis. Gastroenterology 92: 6067, 1987.
62. Beretta E, Malesci A, Zerbi A, Mariani A, Carlucci M, Bonato C, Ferrari AM and Di Carlo V: Serum CA 19-9 in the postsurgical follow-up of patients with pancreatic cancer. Cancer 60: 2428-2431, 1987.
63. Glenn J, Steinberg WM, Kurtzman SH, Steinberg SM and Sindelar WF: Evaluation of the utility of a radioimmunoassay for serum CA 19-9 levels in patients before and after treatment of carcinoma of the pancreas. J Clin Oncol 6: 462-468, 1988.
64. UICC: TNM-Classification of Malignant Tumors, 4th ed. Berlin Heidelberg New York, Springer, 1997.
65. Ishii H, Okada S, Tokuuye K, Nose H, Okusaka T, Yoshimori M, Nagahama H, Sumi M, Kagami Y and Ikeda H: Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma. Cancer 79: 1516-1520, 1997.
66. Willett CG, Daly WJ and Warshaw AL: CA 19-9 is an index of response to neoadjunctive chemoradiation therapy in pancreatic cancer. Am J Surg 172: 350-352, 1996.
67. Rothenberg ML, Abbruzzese JL, Moore M, Portenoy RK, Robertson JM and Wanebo HJ: A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma. Cancer 78: 627-632, 1996.
68. Brambs HJ and Claussen CD: Pancreatic and ampullary carcinoma. Ultrasound, computed tomography, magnetic resonance imaging and angiography. Endoscopy 25: 58-68, 1993.
69. Okusaka T, Okada S, Sato T, Wakasugi H, Saisho H, Furuse J, Ishikawa O, Matsuno S and Yokoyama S: Tumor markers in evaluating the response to radiotherapy in unresectable pancreatic cancer. Hepatogastroenterology 45: 867-872, 1998.
70. Halm U, Schumann T, Schiefke I, Witzigmann H, Mossner J and Keim V: Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer 82: 1013-1016, 2000.
71. Guthoff A, Klapdor U, Klapdor R, Eichfuss HP, Dallek M and Greten H: Diagnosis of recurrence and evaluation of the course of pancreatic cancer. Combined use of sonography and the new tumor marker CA 19-9. Dtsch Med Wochenschr 109: 1410-1412, 1984.
72. Marotta F, Tajiri H, Yoshimori M, Nakamura K and Ozaki H: A nine-year retrospective analysis of resectable pancreatic cancer at the National Cancer Center Hospital in Tokyo: clues to diagnosis and diagnostic assessment. Ital J Gastroenterol 23: 197-201, 1991.
73. Sperti C, Pasquali C, Catalini S, Cappellazzo F, Bonadimani B, Behboo R and Pedrazzoli S: CA 19-9 as a prognostic index after resection for pancreatic cancer. J Surg Oncol 52: 137-141, 1993.
74. Tian F, Appert HE, Myles J and Howard JM: Prognostic value of serum CA 19-9 levels in pancreatic adenocarcinoma. Ann Surg 215: 350-355, 1992.